KZR — Kezar Life Sciences Income Statement
0.000.00%
Last trade - 00:00- $30.83m
- -$91.09m
- 26
- 54
- 51
- 40
Annual income statement for Kezar Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 7 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 43 | 54.7 | 71.2 | 118 | 90.6 |
| Operating Profit | -43 | -54.7 | -71.2 | -111 | -90.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -41.7 | -54.6 | -68.2 | -102 | -83.7 |
| Net Income After Taxes | -41.7 | -54.6 | -68.2 | -102 | -83.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -41.7 | -54.6 | -68.2 | -102 | -83.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -41.7 | -54.6 | -68.2 | -102 | -83.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -9.49 | -10.4 | -10.1 | -13.2 | -11.3 |